148 related articles for article (PubMed ID: 24483347)
61. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Moreau P; San Miguel J; Ludwig H; Schouten H; Mohty M; Dimopoulos M; Dreyling M;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi133-7. PubMed ID: 23956208
[No Abstract] [Full Text] [Related]
62. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
Glavey SV; Ghobrial IM
Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
[TBL] [Abstract][Full Text] [Related]
63. Multiple myeloma and diagnostic imaging.
Reisenbuckler C
Radiol Technol; 2014; 85(4):391-410; quiz 411-3. PubMed ID: 24614435
[TBL] [Abstract][Full Text] [Related]
64. Standardisation of minimal residual disease in multiple myeloma.
Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
[TBL] [Abstract][Full Text] [Related]
65. IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up.
Dejoie T; Lakomy D; Caillon H; Pegourié B; Decaux O
Ann Biol Clin (Paris); 2016 Aug; 74(4):429-41. PubMed ID: 27492696
[TBL] [Abstract][Full Text] [Related]
66. Myeloma ASH 2010 highlights.
Kumar SK
Am J Hematol; 2011 Sep; 86(9):820-3. PubMed ID: 21800357
[No Abstract] [Full Text] [Related]
67. Sensitive multiple myeloma disease monitoring by mass spectrometry.
Santockyte R; Jin C; Pratt J; Ammar R; Desai K; Bolisetty M; Das P; Popa-McKiver M; Puig O
Blood Cancer J; 2021 Apr; 11(4):78. PubMed ID: 33927186
[No Abstract] [Full Text] [Related]
68. Roadmap to cure multiple myeloma.
Rodriguez-Otero P; Paiva B; San-Miguel JF
Cancer Treat Rev; 2021 Nov; 100():102284. PubMed ID: 34597912
[TBL] [Abstract][Full Text] [Related]
69. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.
Caers J; Garderet L; Kortüm KM; O'Dwyer ME; van de Donk NWCJ; Binder M; Dold SM; Gay F; Corre J; Beguin Y; Ludwig H; Larocca A; Driessen C; Dimopoulos MA; Boccadoro M; Gramatzki M; Zweegman S; Einsele H; Cavo M; Goldschmidt H; Sonneveld P; Delforge M; Auner HW; Terpos E; Engelhardt M
Haematologica; 2018 Nov; 103(11):1772-1784. PubMed ID: 30171031
[TBL] [Abstract][Full Text] [Related]
70. [Multiple myeloma-soon curable?].
Goldschmidt H
Internist (Berl); 2021 May; 62(5):562-570. PubMed ID: 33783581
[TBL] [Abstract][Full Text] [Related]
71. Approach to the treatment of multiple myeloma: a clash of philosophies.
Rajkumar SV; Gahrton G; Bergsagel PL
Blood; 2011 Sep; 118(12):3205-11. PubMed ID: 21791430
[TBL] [Abstract][Full Text] [Related]
72. Extramedullary manifestations of multiple myeloma in the thyroid gland and in the lungs: excellent response to therapy.
Weisser F; Reuter C; Taverna C
Ann Hematol; 2010 Nov; 89(11):1183-4. PubMed ID: 20383503
[No Abstract] [Full Text] [Related]
73. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances.
Garderet L; D'Souza A; Jacobs P; van Biezen A; Schönland S; Kroeger N; Morris C; Hari P
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1193-1202. PubMed ID: 28285082
[TBL] [Abstract][Full Text] [Related]
74. [Thoracic involvement of multiple myeloma (MM) with light chains: Rare entity (about a case)].
Benkirane B; Jabri H; ElKhattabi W; Afif H
Rev Pneumol Clin; 2017 Jun; 73(3):151-152. PubMed ID: 28431789
[No Abstract] [Full Text] [Related]
75. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma.
Natsuhara KH; Huang CY; Knoche J; Arora S; Chung A; Martin T; Wolf J; Wong SW; Shah N; Banerjee R
Leuk Lymphoma; 2023 Jun; 64(6):1186-1193. PubMed ID: 37096638
[TBL] [Abstract][Full Text] [Related]
76. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VI. Standard Treatment for Multiple Myeloma].
Ito S; Takano M
Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1238-45. PubMed ID: 30168968
[No Abstract] [Full Text] [Related]
77. Cast Nephropathy in the Setting of Diffuse Carcinomatosis of Unknown Origin.
Plotkin E; Benchetrit S; Zahavi T; Kimhi O; Korzets Z
Isr Med Assoc J; 2015 Dec; 17(12):780-2. PubMed ID: 26897983
[No Abstract] [Full Text] [Related]
78. The burden of myeloma: novel approaches to disease assessment.
Ho M; Kourelis T
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):356-362. PubMed ID: 36485143
[TBL] [Abstract][Full Text] [Related]
79. Pursuing the curative blueprint for early myeloma.
Roschewski M; Korde N; Wu SP; Landgren O
Blood; 2013 Jul; 122(4):486-90. PubMed ID: 23782936
[TBL] [Abstract][Full Text] [Related]
80. Chronic neutrophilia preceding overt aggressive light chain multiple myeloma.
Fukuno K; Tsurumi H; Kanemura N; Tanabashi S; Okamoto K; Moriwaki H
Leuk Lymphoma; 2006 Apr; 47(4):762-4. PubMed ID: 16886279
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
